Skip to main content

MIT’s new pill sticks to your gastrointestinal tract for a slow, long-term drug release

For people who don’t like taking medication in pill form, getting the right medical treatment can be difficult. That’s why researchers at MIT have developed a new type of pill that slowly releases long-term doses of medication from within the gastrointestinal tract. The pill would also help patients who need to take ingestible drugs multiple times throughout the day by limiting dosage to a single extended-release tablet.

The MIT research team used a mucoadhesive polymer called Carbopol to design the pill, since the material naturally adheres to mucosal surfaces like the lining of the stomach and intestines. Once a patient takes the medication, one side of the pill sticks to the wall of the gastrointestinal tract to keep it in place. Meanwhile, the other side of the pill relies on a special omniphobic coating that repels all food and liquids so they can slide by without knocking the pill out of place. This protective coating is made of fluorinated and lubricated cellulose acetate, with a surface texture inspired by the lotus leaf to repel any particle that might pass.

Recommended Videos

The pill’s “janus” design, named after the two-faced mythical god, is what makes the pill so groundbreaking. Past trials of ingestible extended-release drugs resulted in blockages in the gastrointestinal tract or disappearing pills that were knocked away by passing food and liquids. In today’s medical technology landscape, extended-release drug solutions are increasingly common. But these long-term drugs are usually administered through implantable devices (which means minor surgery for the patient) or experimental patches that adhere to the skin.

So far, MIT’s janus pill is still in the testing phase to measure how long tablets can stay attached to the lining of organs along the GI tract, and to determine the rate of the extended drug release. Once it is ready for the general public, scientists believe that the pill could be used for everything from antibiotics to malaria and tuberculosis drugs.

Chloe Olewitz
Former Digital Trends Contributor
Chloe is a writer from New York with a passion for technology, travel, and playing devil's advocate. You can find out more…
The Ioniq 5 is once again eligible for the $7,500 tax credit
2025 Hyundai Ioniq 5

After a brief and confusing absence, the Hyundai Ioniq 5 is once again eligible for the full $7,500 federal tax credit — and this time, it's sticking around (at least for now). So, what happened? Let’s unpack the ride.

The Ioniq 5, a sleek and tech-savvy electric crossover, initially made headlines not just for its design, but for being built at Hyundai’s brand-new Metaplant in Georgia. That domestic assembly qualified it for the EV tax credit under the Inflation Reduction Act (IRA), which requires vehicles to be made in North America with batteries sourced from trade-friendly countries. But early in 2025, the Ioniq 5 vanished from the list. Why? Likely due to its battery packs, which were then still being sourced from SK On’s Hungarian facility.

Read more
Sebastian Stan lays out Bucky’s future after Thunderbolts
Sebastian Stan in Thunderbolts.

There are some spoilers ahead for the ending of Marvel's Thunderbolts. Stop reading now if you don't want to be spoiled.

Earlier this year, Captain America: Brave New World briefly introduced a new direction for James "Bucky" Barnes, a character Sebastian Stan has been playing since 2011 in Captain America: The First Avenger. In Brave New World, the former Winter Soldier apparently retired from being a reformed hero and went into politics by running for Congress. Thunderbolts reveals that Bucky won his election to the House of Representatives. But his stay in Congress was short.

Read more
Jeep Compass EV breaks cover—but will it come to the U.S.?
jeep compass ev us newjeepcompassfirsteditionhawaii  4

Jeep just pulled the wraps off the all-new Compass EV, and while it’s an exciting leap into the electric future, there's a catch—it might not make it to the U.S. anytime soon.
This is a brand new electric version of the Jeep Compass, and being built on Stellantis' STLA platform—the same architecture underpinning models like the Peugeot E-3008 and E-5008—it looks much slicker and packs a lot more inside than previous versions of the Compass.
Let’s start with what’s cool: the new Compass EV is packing up to 404 miles of range on a single charge, a 74 kWh battery, and fast-charging that gets you from 20% to 80% in about 30 minutes. Not bad for a compact SUV with Jeep's badge on the nose.
There are two versions: a front-wheel-drive model with 213 horsepower and a beefier all-wheel-drive version with 375 horsepower. That AWD setup isn’t just for looks—it can handle 20% inclines even without front traction, and comes with extra ground clearance and better off-road angles. In short, it’s still a Jeep.
The design's been refreshed too, and inside you’ll find the kind of tech and comfort you’d expect in a modern EV—sleek, smart, and ready for both city streets and dirt trails.
But here’s the thing: even though production starts soon in Italy, Jeep hasn’t said whether the Compass EV is coming to America. And the signs aren’t promising.
Plans to build it in Canada were recently put on hold, with production now delayed until at least early 2026. Some of that might have to do with possible U.S. tariffs on Canadian and Mexican vehicles—adding a layer of uncertainty to the whole rollout.
According to Kelley Blue Book, a Stellantis spokesperson confirmed that the company has “temporarily paused work on the next-generation Jeep Compass, including activities at” the Canadian plant that was originally meant to build the model. They added that Stellantis is “reassessing its product strategy in North America” to better match customer needs and demand for different powertrain options.
So while Europe and other markets are gearing up to get the Compass EV soon, American drivers might be left waiting—or miss out entirely.
That’s a shame, because on paper, this electric Jeep hits a lot of sweet spots. Let’s just hope it finds a way over here.

Read more